ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.856,48
-0,77%
S&P 500
5.827,04
-1,54%
US Dollar vs BRL
6,12417
0,00%
Bitcoin
94.294,77
-0,29%
Brent Oil
79,285
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Brainstorm Cell Therapeutics Inc (BCLI)

  7. Brainstorm Cell Therapeutics Inc (BCLI) Notícias

BCLI

Brainstorm Cell Therapeu... (BCLI)

Brainstorm Cell Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BCLI
DataHoraFonteTítuloCódigoCompanhia
07/01/202518:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
07/01/202518:10Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
14/11/202418:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
14/11/202418:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
14/11/202417:24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
30/09/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
24/09/202417:30Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
17/09/202416:32Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
16/08/202408:03Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
16/08/202408:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
06/08/202417:59Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
05/08/202418:11Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
31/07/202417:09Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
24/07/202409:30PR Newswire (Canada)BCLI Update - Progress Supports Our 10x Plus Value Range PotentialNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
14/06/202413:01PR Newswire (US)BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness ExpectationNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
27/02/202408:30PR Newswire (US)BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferenceNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
23/02/202408:00PR Newswire (US)BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
13/02/202408:30PR Newswire (US)BrainStorm Cell Therapeutics to Present at European Life Sciences CEO ForumNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
12/02/202412:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
18/12/202307:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
22/11/202318:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
27/09/202311:10AllPennyStocks.comBiotech Shares Halted Premarket As FDA Reviews ApplicationNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
19/07/202310:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
21/06/202317:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
21/06/202317:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
20/06/202318:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
15/05/202308:31Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
05/04/202311:47Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
10/11/202211:44TipRanksBrainstorm Plummets After the FDA Rejects ApplicationNASDAQ:BCLIBrainstorm Cell Therapeutics Inc
16/09/202213:45TipRanksMaxim Group Remains a Buy on Brainstorm Cell Therapeutics (BCLI)NASDAQ:BCLIBrainstorm Cell Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BCLI

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AMER3
Americanas ON
BOV
PRIO3
PETRORIO ON
BOV
BRAV3
Brava Energia ON
BOV
FICT3
Fictor Alimentos ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados